CrushSCI.com
Journal Selection & Manuscript Polishing Services
Targeted Oncology journal cover Medicine
Back to journal directory

Review Cycle Records

Targeted Oncology

Springer SCIE Non-OA
2026 Emerging Zone 22025 CAS Zone 32025 JCR Q2
83.9Average days
75Median days
31Fastest days
165Longest days
712025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

45 days

Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond

AuthorsHendrik Schürmann; Wungki Park; Grainne M. O’Kane; Carolina Sciortino; Monica Niger; Maximilian Reichert; Kenneth P. Olive; Ina Pretzell; C. Benedikt Westphalen

Affiliations1. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 2. Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 3. German Cancer Consortium (DKTK), Partner Site Essen, a Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany; 4. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; 5. Weill Cornell Medical College, New York, USA; 6. David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, USA; 7. St. Vincent’s University Hospital and School of Medicine, University College Dublin, Dublin, Republic of Ireland; 8. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 9. Center for Translational Pancreatic Cancer Research, TUM School of Medicine and Health, Department of Clinical Medicine, Clinical Department for Internal Medicine II, TUM University Hospital, Technical University of Munich, Munich, Germany; 10. Center for Organoid Systems (COS), Munich Institute of Biomedical Engineering (MIBE), Technical University Munich (TUM), Garching, Germany; 11. German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between German Cancer Research Center (DKFZ) and TUM University Hospital, Munich, Germany; 12. Bavarian Cancer Research Center (BZKF), Munich, Germany; 13. Department of Medicine, Division of Digestive and Liver Diseases, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA; 14. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA; 15. West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 16. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; 17. German Cancer Consortium (DKTK), Partner Site Munich, a Partnership Between German Cancer Research Center (DKFZ) and University Hospital of the LMU Munich, Munich, Germany; 18. Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Munich, Munich, Germany

Source PDF DOI Publisher page
105 days

From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board

AuthorsTabea Fröhlich; Ulrich Lehmann; Tanja Reineke-Plaaß; Thomas Wirth; Sabrina Welland; Chen Du; Bernd Auber; Benjamin-Alexander Bollmann; Philipp Ivanyi; Tjoung-Won Park-Simon; Diana Steinmann; Christian Hartmann; Ariana de Oliviera Mekonnen; Anja Heutling; Andrea Schütte; Hans Heinrich Wedemeyer; Florian Heinrich Heidel; Susanne Isfort; Arndt Vogel; Anna Saborowski

Affiliations1. Center for Personalized Medicine (Zentrum für Personalisierte Medizin, ZPM), Comprehensive Cancer Center (CCC) Hannover (Claudia von Schilling Center), Hannover Medical School, Hannover, Germany; 2. Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School, Hannover, Germany; 3. PRACTIS Clinician Scientist Program, Dean’s Office for Academic Career Development, Hannover Medical School, Hannover, Germany; 4. Institute of Pathology, Hannover Medical School, Hannover, Germany; 5. Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; 6. Institute of Human Genetics, Hannover Medical School, Hannover, Germany; 7. Department of Pneumology and Infectious Diseases, Hannover Medical School, Hannover, Germany; 8. Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; 9. Department of Radiation Oncology and Special Oncology, Hannover Medical School, Hannover, Germany; 10. Department of Neuropathology, Institute of Pathology, Hannover Medical School, Hannover, Germany; 11. Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; 12. Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Schwartz Reisman Liver Research Centre, Toronto, Canada

Source PDF DOI Publisher page
39 days

Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA

AuthorsMatthew S. Block; Ashley E. Stenzel; Rene Marcotte; Katrine L. Wallace

Affiliations1. Mayo Clinic, Comprehensive Cancer Center, Rochester, USA; 2. Replimune Inc, Woburn, USA; 3. RCM Consulting, Attleboro, USA; 4. University of Illinois Chicago, School of Public Health, Chicago, USA

Source PDF DOI Publisher page
134 days

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies

AuthorsAnikó Katalin Valikovics; Dániel Bacsó; Nadeen Samaien; Isabel Pinto Amorim das Virgens; Boglárka Szentes; Gergely Agócs; Mahmoud Obeidat; Tamás Széll; Boris Hadaschik; Péter Hegyi; Péter Nyirády; Tibor Szarvas

Affiliations1. Centre for Translational Medicine, Semmelweis University, Budapest, Hungary; 2. Department of Urology, Semmelweis University, Budapest, Hungary; 3. Department of Urology, University of Duisburg-Essen and German Cancer Consortium, Essen, Germany; 4. Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary; 5. Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary

Source PDF DOI Publisher page
74 days

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma

AuthorsSai Sanikommu; Alejandro N. Santos; Bashar Dawoud; Khushi H. Shah; Sima Vazquez; Ashish H. Shah; Victor M. Lu

Affiliations1. Department of Neurosurgery, Miller School of Medicine, University of Miami, Miami, USA

Source PDF DOI Publisher page
70 days

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR -Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis

AuthorsYen-Hsiang Huang; Kuo-Hsuan Hsu; Jeng-Sen Tseng; Po-Hsin Lee; I-Hung Lin; Mu-Han Peng; Tsung-Ying Yang

Affiliations1. Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 2. Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung, Taiwan; 3. School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; 4. Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan; 5. Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan; 6. Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; 7. Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung, Taiwan

Source PDF DOI Publisher page
76 days

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker

AuthorsHiroki Ishihara; Takayuki Nakayama; Hironori Fukuda; Nanaka Katsurayama; Yuki Nemoto; Shinsuke Mizoguchi; Hiroaki Shimmura; Yasunobu Hashimoto; Atsuko Seki; Kazuhiko Yoshida; Junpei Iizuka; Tsunenori Kondo; Yoji Nagashima; Toshio Takagi

Affiliations1. Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan; 2. Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan; 3. Department of Urology, Tokyo Women’s Medical University Adachi Medical Center, Tokyo, Japan; 4. Department of Urology, Jyoban Hospital, Iwaki, Japan; 5. Department of Urology, Saiseikai Kazo Hospital, Kazo, Japan

Source PDF DOI Publisher page
31 days

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

AuthorsMichael A. Liu; Kyle Miyazaki; Karie Runcie; Hanna Cash; Lingbin Meng

Affiliations1. Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA; 2. Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, USA; 3. Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA

Source PDF DOI Publisher page
100 days

Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review

AuthorsChin Hang Yiu; Gwyneth Yuet Yin Leung; Isabelle C. Lee; Christine Y. Lu

Affiliations1. The University of Sydney, School of Pharmacy, Camperdown, Australia; 2. Kolling Institute, Faculty of Medicine and Health, The University of Sydney and the Northern Sydney Local Health District, Sydney, Australia; 3. Department of Pharmacy, Royal North Shore Hospital, St Leonards, Australia

Source PDF DOI Publisher page
165 days

Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial

AuthorsYu Sunakawa; Hisateru Yasui; Manabu Shiozawa; Hiroyuki Takeda; Naoya Akazawa; Tamotsu Sagawa; Kazuhiro Shiraishi; Takahisa Kyogoku; Takashi Mine; Yasuhiro Yuasa; Takanori Watanabe; Tatsuya Kinjo; Yoshihiro Okita; Hiroyuki Okuyama; Satoshi Yuki; Koki Miyakawa; Ayana Kobara; Shoko Yanaka; Yukiko Abe; Wataru Ichikawa; Masashi Fujii; Akihito Tsuji

Affiliations1. Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan; 2. Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan; 3. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan; 4. Department of Gastroenterological Surgery, Sendai City Medical Center Sendai Open Hospital, Sendai, Japan; 5. Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; 6. Department of Medical Oncology, NHO Nagoya Medical Center, Nagoya, Japan; 7. Department of Surgery, Kobe City Nishi-Kobe Medical Center, Kobe, Japan; 8. Department of Clinical Oncology, Nagasaki Harbor Medical Center, Nagasaki, Japan; 9. Department of Gastrointestinal Surgery, Tokushima Red Cross Hospital, Tokushima, Japan; 10. Department of Surgery, Japanese Red Cross Society Himeji Hospital, Himeji, Japan; 11. Department of Surgery, Tokushima Municipal Hospital, Tokushima, Japan; 12. Division of Digestive and General Surgery, University of the Ryukyus, Ginowan, Japan; 13. Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan; 14. Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan; 15. Sysmex Corporation, Kobe, Japan; 16. G&G SCIENCE CO., LTD., Fukushima, Japan; 17. Division of Medical Oncology, Showa Medical University Fujigaoka Hospital, Yokohama, Japan; 18. Japan Clinical Cancer Research Organization, Tokyo, Japan

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.